New drug duo aims to attack Tough-to-Treat breast cancer
NCT ID NCT05633979
Summary
This early-stage study is testing a new combination of two drugs, valemetostat and trastuzumab deruxtecan, for people with advanced breast cancer that has low or no HER2 protein. The main goals are to find a safe dose of the drug combination and to see if it causes tumors to shrink. The study is for adults whose cancer has spread and who have already tried other treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.